MindSens has won the III Global Graphene Call with its groundbreaking device for dementia diagnosis: an affordable and portable as well as accurate domestic-use tool that could bring early dementia detection to households and clinics worldwide.
The London-based start-up MindSens is one of the winners of the III Global Graphene Call. The event consists of an international convocation, organized by CIC nanoGUNE, BerriUp, Graphenea, Fomento de San Sebastián, and BIC Gipuzkoa, which seeks innovative ideas that harness the potential of graphene in industrial and technological applications.
The company is developing a low-cost, portable device for the early detection of dementia, even before symptoms appear, at University College London (UCL). The international call, launched by CIC nanoGUNE, BerriUp, Graphenea, Fomento de San Sebastián, and BIC Gipuzkoa, aims to find breakthrough ideas that explore the industrial and technological potential of graphene.
MindSens, a UK-based project, is working on a device that can identify early signs of Alzheimer’s disease using just a single drop of blood. The device incorporates graphene in its sensors, utilizing a graphene field-effect transistor (GFET). In this system, functionalized graphene surfaces interact with specific target analytes, altering the device’s conductivity and enabling highly precise detection.
With an interdisciplinary and international team of six professionals from countries including the UK, Sweden, and Indonesia, and with clearly defined roles (going from executive leadership and business development to product design, software development, and R&D) this spin-off project is now searching for the ideal location to establish the company.
Currently, Rica Asrosa, a scientific researcher from Indonesia who is completing her PhD in materials science at University College London (UCL), is in San Sebastián working on product development at nanoGUNE, thanks to the III Global Graphene Call award. The team’s goal is to launch a spin-off company focused on making brain health diagnostics more accessible, starting with dementia and eventually expanding to other neurodegenerative diseases.
To know more [click here]
